? 關(guān)鍵詞 逆轉(zhuǎn)錄因子 內(nèi)分泌 干擾素調(diào)節(jié)因子 飽和突變?PD-1檢查點(diǎn) 曲妥珠單抗 多塔利單抗 恩沃利單抗? ?

#今日行業(yè)熱點(diǎn)#

①Science：Genome editing with retroelements 觀點(diǎn)：利用逆轉(zhuǎn)錄因子進(jìn)行基因組編輯 DOI: 10.1126/science.adi3183

Genome editing with retroelements | Science

②Science：Unbiased transcription factor CRISPR screen identifies ZNF800 as master repressor of enteroendocrine differentiation 基于CRISPR的功能篩選確定ZNF800是調(diào)控內(nèi)分泌轉(zhuǎn)錄因子網(wǎng)絡(luò)的關(guān)鍵因子 DOI: 10.1126/science.adi2246

Unbiased transcription factor CRISPR screen identifies ZNF800 as master repressor of enteroendocrine differentiation | Science

③Science Advances：IRF1 regulates self-renewal and stress responsiveness to support hematopoietic stem cell maintenance 干擾素調(diào)節(jié)因子1 (IRF1)通過調(diào)節(jié)自我更新和應(yīng)激反應(yīng)來支持造血干細(xì)胞(HSCs)的維持 DOI: 10.1126/sciadv.adg5391

IRF1 regulates self-renewal and stress responsiveness to support hematopoietic stem cell maintenance | Science Advances

④Science Advances：Saturation mutagenesis of α-synuclein reveals monomer fold that modulates aggregation α-突觸核蛋白(aSyn)飽和突變揭示了調(diào)節(jié)aSyn聚集的調(diào)節(jié)因子 DOI: 10.1126/sciadv.adh3457

Saturation mutagenesis of α-synuclein reveals monomer fold that modulates aggregation | Science Advances

⑤Science Advances：Stromal BMP signaling regulates mucin production in the large intestine via interleukin-1/17 基質(zhì)骨形態(tài)發(fā)生蛋白(BMP)信號(hào)通過IL-1和IL-17調(diào)節(jié)大腸黏蛋白的產(chǎn)生 DOI: 10.1126/sciadv.adi1827

Stromal BMP signaling regulates mucin production in the large intestine via interleukin-1/17 | Science Advances

⑥Science Translational Medicine：DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity DGKα/ζ抑制劑聯(lián)合PD-1檢查點(diǎn)療法促進(jìn)T細(xì)胞介導(dǎo)的抗腫瘤免疫 DOI: 10.1126/scitranslmed.adh1892

DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell–mediated antitumor immunity | Science Translational Medicine

⑦曲妥珠單抗生物類似藥上市申請(qǐng)已獲得批準(zhǔn)；同時(shí)申請(qǐng)適應(yīng)癥外推，擬定適應(yīng)癥為：HER2陽(yáng)性早期乳腺癌、HER2陽(yáng)性轉(zhuǎn)移性乳腺癌、HER2陽(yáng)性轉(zhuǎn)移性胃癌 ⑧PD-1抑制劑多塔利單抗(Dostarlimab)用于原發(fā)性晚期或復(fù)發(fā)性子宮內(nèi)膜癌的Ⅲ期臨床RUBY達(dá)到總生存期（OS）的主要終點(diǎn) ⑨高選擇性內(nèi)皮素A（ETA）受體抑制劑Atrasentan用于IgA腎病的III期ALIGN研究達(dá)到主要終點(diǎn) ⑩PD-L1抗體恩沃利單抗獲FDA批準(zhǔn)開展Ⅲ期臨床，評(píng)估恩沃利單抗聯(lián)合侖伐替尼對(duì)比鉑類用于錯(cuò)配修復(fù)完整（pMMR）晚期或復(fù)發(fā)性子宮內(nèi)膜癌患者的有效性與安全性 科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為